According to a new report published by AkVis Intelligence, titled, “Antibody Drug Conjugates Market by Product Type, Application, Technology, Target Type, End–-Users, and Region Global Market Analysis and Forecast, 2024-2032.
The Global Antibody Drug Conjugates Market Size Was Valued at USD 9.7 Billion in 2023 and is Projected to Reach USD 35.21 Billion by 2032, Growing at a CAGR of 15.4 % from 2024-2032.
Antibody Drug Conjugates (ADCs) are focused medications designed to carry cytotoxic drugs, particularly to cancer cells. They consist of a monoclonal antibody, a cytotoxic payload, and a linker molecule. ADCs combine the accuracy of monoclonal antibodies with the potent cytotoxicity of chemotherapy medications. They target cancer cells directly, reducing damage to normal cells and reducing side effects compared to traditional chemotherapy. ADCs are increasingly used in various types of cancer, such as breast cancer, lymphoma, and leukemia. They offer better effectiveness and reduced overall toxicity compared to conventional chemotherapy. The market for ADCs is driven by the increasing global prevalence of cancer, with the number of newly diagnosed cases projected to reach 27.5 million by 2040.
According to the Antibody Drug Conjugates, the Market is segmented into Product Type, Application, Technology, Target Type, and End–users. By Product type, the market is categorized into Adcetris, Kadcyla, and Other Product Type. By Application, the market is categorized into Blood Cancer, Breast Cancer, Ovary Cancer, Lung Cancer, Skin Cancer, Brain Tumor, and Others. By Technology, the market is categorized into Cleavable Linker and Non-Cleavable Linker. By Target type, the market is segmented into CD30 Antibodies, HER2 Antibodies, and Other Target Types. By End User, the market is categorized into Hospitals and Specialty Cancer Centers, Biotechnology and Pharmaceutical Companies, and Other End Users. By region, it is analysed across North America (U.S.; Canada; Mexico), Europe (Germany; U.K.; France; Italy; Russia; Spain, etc.), Asia-Pacific (China; India; Japan; Southeast Asia, etc.), South America (Brazil; Argentina, etc.), Middle East & Africa (Saudi Arabia; South Africa, etc.).
Antibody-drug conjugates (ADCs) are essential in cancer therapy due to their ability to target tumor cells and minimize damage to healthy tissue. As cancer rates increase globally, there is a need for specific treatments. ADCs are adaptable in personalized healthcare, enhancing patients' quality of life. As people age, changes in cells and reduced repair processes increase the need for ADCs, highlighting their importance in adapting to the changing cancer treatment scene.
The aging population presents a significant opportunity for growth in the Antibody Drug Conjugates (ADCs) industry, as the elderly face cancers like colon and breast cancer, which can be effectively treated with ADCs. The complexity of the detection and treatment of lung cancer underscores the need for advanced therapies like ADCs. The trend toward an aging population is promoting innovation in cancer therapy and enhancing treatment results and overall well-being for elderly individuals worldwide.
Global Antibody Drug Conjugates Market, Segmentation
The Antibody Drug Conjugates Market is Segmented Based on Product Type, Application, Technology, Target Type, and End–Users, and Region.
By Technology,
The Cleavable Linker segment is expected to dominate the market during the forecast period. The revenue share of the fissile fasteners segment was the largest in 2023 at 72.43%, which was attributed to the fissile fasteners segment. Cleavable linkers are the most commonly used technology in ADCs in cancer therapy because they can remain stable in the bloodstream for a longer time and effectively release cytotoxic agents. Cleavable linker technology is a major advance in antibody-drug conjugates, enabling the targeted release of cytotoxic payloads into cancer cells, ultimately improving treatment efficacy. The use of cleavable linker technology enables the delivery of effective drugs to the desired location, ensuring a gradual release of the harmful cargo to ensure maximum impact on cancer cells while protecting healthy tissues. Cleavable linkers are the most common technology used to maintain the efficacy of ADCs in cancer therapy due to their ability to release cytotoxic agents and remain stable in the bloodstream for long periods.
By Product Type:
The Kadcyla segment had the majority. In 2023, the Kadcyla segment rose to power in the ADC market due to its significant revenue growth. The increase is due to the increase in breast cancer cases worldwide and the approval of ADC therapy for breast cancer. In January 2022, F. Hoffmann-La Roche Ltd. reached a major milestone by gaining approval for Kadcyla in China, a crucial step in a growing market. In 2023, Roche more than halved the price of Kadcyla in China to increase its market influence through competitive pricing tactics. Thanks to this move, China rose from 10th place to 2nd place in Roche's global market position. Roche's flexible pricing strategy demonstrates its ability to adapt to changing market conditions, especially in China's growing pharmaceutical sector.
Region:
The North American antibody-drug conjugates market is expected to dominate the market over the forecast period, with a revenue share of 52.54% in 2023. This dominance is expected to continue due to new product releases, increasing cancer cases, ongoing drug development, and major industry leaders like Pfizer, AstraZeneca, and Gilead Sciences. Growth is expected due to increased awareness of treatment options, favorable reimbursement policies, increased research and development spending, and improved patient accessibility. The rising incidence of cancer and the need for targeted treatments will drive market growth. Key players, advanced healthcare infrastructure, and robust R&D facilities have contributed to market growth. Common risk factors for cancer include tobacco use, obesity, heavy alcohol consumption, and exposure to infectious agents. ADC developers are providing patient assistance programs to boost usage.
Some of The Leading/Active Market Players Are-
- Seattle Genetics: (U.S.)
- Pfizer: (U.S.)
- Bristol Myers Squibb: (U.S.)
- Gilead Sciences (Immunomedics): (U.S.)
- AbbVie: (U.S.)
- Merck & Co.: (U.S.)
- Johnson & Johnson: (U.S.)
- Mersana Therapeutics: (U.S.)
- Seagen Inc.: (U.S.)
- ImmunoGen, Inc.: (U.S.) and Other Active Players
Key Industry Developments
- In January 2024, WuXi XDC and Celltrion announced the signing of a Memorandum of Understanding (MOU) aimed at enhancing integrated services for antibody-drug conjugates (ADCs). As leaders in their respective fields—WuXi XDC in Contract Research, Development, and Manufacturing Organization (CRDMO) services for ADCs, and Celltrion in biopharmaceutical innovation—the MOU focused on the comprehensive development and manufacturing of bioconjugates. This collaboration underscores their commitment to advancing therapeutic solutions globally, leveraging combined expertise to drive innovation in bioconjugate technologies.
- In March 2024, in a significant move bolstering its oncology pipeline, Johnson & Johnson (NYSE: JNJ) has completed the acquisition of Ambrx Biopharma, Inc. The all-cash merger, valued at approximately $2.0 billion ($1.9 billion net of acquired cash), enhances Johnson & Johnson’s capabilities in prostate cancer treatment and expands its portfolio of next-generation antibody-drug conjugates (ADCs). Ambrx, known for its synthetic biology technology platform, specializes in developing targeted oncologic therapeutics, reinforcing Johnson & Johnson’s commitment to advancing innovative cancer treatments.
Key Findings of the Study:
- Cleavable linker technology dominates the ADC market due to its ability to release cytotoxic agents selectively and remain stable in the bloodstream.
- Kadcyla is a leading product type in the market, driven by its approval for breast cancer treatment and strategic pricing adjustments.
- North America leads the global ADC market, accounting for 52.54% of revenue in 2023, supported by advanced healthcare infrastructure, R&D investments, and favorable reimbursement policies
T. Kumbhar
Author Information
T. Kumbhar is a Senior Market Research Consultant at IMR, specializing in Agro-Chemicals, Food Tech, Consumer Goods, and more. With four years of experience, he delivers market insights, competitive analysis, and data-driven business strategies.
